Orlistat inhibits dietary cholesterol absorption

Obesity Research

Volumn 9, Issue 10, 2001, Pages 599-604

  Mittendorfer, Bettina ^a   Ostlund Jr , Richard E ^a   Patterson, Bruce W ^a   Klein, Samuel ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cholesterol; Orlistat; Stable isotope; Weight loss

Indexed keywords

ANTIOBESITY AGENT; ENZYME INHIBITOR; LACTONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL LIPASE;

ADULT; ARTICLE; BLOOD; CHOLESTEROL INTAKE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; FEMALE; HUMAN; INTESTINE; INTESTINE ABSORPTION; ISOTOPE LABELING; MALE; METABOLISM; OBESITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY;

ADULT; ANTI-OBESITY AGENTS; CHOLESTEROL, DIETARY; CHOLESTEROL, LDL; CROSS-OVER STUDIES; ENZYME INHIBITORS; FEMALE; HUMANS; INTESTINAL ABSORPTION; INTESTINES; ISOTOPE LABELING; LACTONES; LIPASE; MALE; OBESITY; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS;

EID: 0035491783     PISSN: 10717323     EISSN: None     Source Type: Journal    
DOI: 10.1038/oby.2001.79     Document Type: Article

References (32)

1. Terry RB, Wood PD, Haskell WL, Stefanick ML, Krauss RM. Regional adiposity patterns in relation to lipids, lipoprotein cholesterol, and lipoprotein subfraction mass in men. J Clin Endocrinol Metab. 1989;68:191-9.
2. Brown CD, Higgins M, Donato KA, et al. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res. 2000;8:605-19.
3. Wald NJ, Law MR. Serum cholesterol and ischemic heart disease. Atherosclerosis. 1995;118(suppl):S1-S5.
4. Sprecher DL. Triglycerides as a risk factor for coronary artery disease. Am J Cardiol 1998;82:49U-56U, discussion 85U-86U.
5. Zambon A, Hokanson JE. Lipoprotein classes and coronary disease regression. Curr Opin Lipidol. 1998;9:329-36.
6. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults.Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Am J Clin Nutr. 1998; 68:899-917.
7. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr. 1992;56:320-8.
8. McGuire MT, Wing RR, Klem ML, Lang W, Hill JO. What predicts weight regain in a group of successful weight losers? J Consult Clin Psychol. 1999;67:177-85.
9. Hadvary P, Lengsfeld H, Wolfer H. Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. Biochem J. 1988;256:357-61.
10. Zhi J, Melia AT, Guerciolini R, et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther. 1994;56:82-5.
11. Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998;352:167-72.
12. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA. 1999;281:235-42.
13. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study. Diabetes Care. 1998; 21:1288-94.
14. Lehtimaki T, Moilanen T, Solakivi T, Laippala P, Ehnholni C. Cholesterol-rich diet induced changes in plasma lipids in relation to apolipoprotein E phenotype in healthy students. Ann Med. 1992;24:61-6.
15. Anderson JT, Grande F, Keys A. Independence of the effects of cholesterol and degree of saturation of the fat in the diet on serum cholesterol in man. Am J Clin Nutr. 1976;29: 1184-9.
16. Hegsted DM, McGandy RB, Myers ML, Stare FJ. Quantitative effects of dietary fat on serum cholesterol in man. Am J Clin Nutr. 1965;17:281-95.
17. Beynen AC, Katan MB. Effect of egg yolk feeding on the concentration and composition of serum lipoproteins in man. Atherosclerosis. 1985;54:157-66.
18. Oh SY, Miller LT. Effect of dietary egg on variability of plasma cholesterol levels and lipoprotein cholesterol. Am J Clin Nutr. 1985;42:421-31.
19. Sarkkinen E, Korhonen M, Erkkila A, Ebeling T, Uusitupa M. Effect of apolipoprotein E polymorphism on serum lipid response to the separate modification of dietary fat and dietary cholesterol. Am J Clin Nutr. 1998;68: 1215-22.
20. Grande F, Anderson JT, Chlouverakis C, Proja M, Keys A. Effect of dietary cholesterol on man's serum lipids. J Nutr. 1965;87:52-62.
21. Bosner MS, Ostlund RE Jr, Osofisan O, Grosklos J, Fritschle C, Lange LG. Assessment of percent cholesterol absorption in humans with stable isotopes. J Lipid Res. 1993; 34:1047-53.
22. Zilversmit DB. A single blood sample dual isotope method for the measurement of cholesterol absorption in rats. Proc Soc Exp Biol Med. 1972;140:862-5.
23. Zilversmit DB, Hughes LB. Validation of a dual-isotope plasma ratio method for measurement of cholesterol absorption in rats. J Lipid Res. 1974;15:465-73.
24. Zilversmit DB. A model for cholesterol absorption: isotope vs. mass; single dose vs. constant infusion. J Lipid Res. 1983;24:297-302.
25. Bosner MS, Lange LG, Stenson WF, Ostlund RE Jr. Percent cholesterol absorption in normal women and men quantified with dual stable isotopic tracers and negative ion mass spectrometry. J Lipid Res. 1999;40:302-8.
26. Goodman DW, Noble RP. Turnover of plasma cholesterol in man. J Clin Invest. 1968;47:231-241.
27. Simmonds WJ, Hofmann AF, Theodor E. Absorption of cholesterol from a micellar solution: intestinal perfusion studies in man. J Clin Invest. 1967;46:874-90.
28. Hill JO, Hauptman J, Anderson JW, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr. 1999;69:1108-16.
29. Dietschy JM. Theoretical considerations of what regulates low-density-lipoprotein and high-density-lipoprotein cholesterol. Am J Clin Nutr. 1997;65:1581S-9S.
30. Spady DK. Hepatic clearance of plasma low density lipoproteins. Semin Liver Dis. 1992;12:373-85.
31. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? Br Med J. 1994;308:367-72.
32. McNamara DJ, Davidson NO, Samuel P, Ahrens EH Jr. Cholesterol absorption in man: effect of administration of clofibrate and/or cholestyramine. J Lipid Res. 1980;21:1058-64.